Vaccine adjuvant K3-SPG offers mice temporary shield against respiratory viruses

When a novel respiratory virus emerges, the world often faces a painful gap: the weeks and months between the recognition of a threat and the availability of a vaccine that can protect against it. The COVID-19 pandemic demonstrated both how quickly vaccine development can move and how much harm can occur before those vaccines reach the public. A new study from researchers at The Institute of Medical Science, The University of Tokyo, published in Science Advances on October 9, 2026, explores a different strategy for closing that gap—one that does not depend on knowing which pathogen is coming. The work, led by Professor Ken Ishii of the Division of Vaccine Science, suggests that a vaccine adjuvant called K3-SPG can temporarily prime the innate immune system in mice, offering measurable protection against influenza A virus and SARS-CoV-2 without prior exposure to either pathogen.

The approach rests on a fundamental distinction within the immune system. Adaptive immunity, which vaccines traditionally harness, learns to recognize specific molecular targets and builds long-lasting, pathogen-specific memory. Innate immunity, by contrast, is the body’s first line of defense and can respond to threats without ever having encountered them before. In recent years, immunologists have described a phenomenon known as trained immunity, in which certain stimuli leave innate immune cells in a heightened state of responsiveness, effectively giving the front-line defenses a temporary boost. However, important questions have remained about how long such protection can persist and which cells are responsible for maintaining it in the respiratory tract, the entry point for influenza, coronaviruses, and many other pandemic threats.

To address these gaps, the research team investigated how K3-SPG modulates innate immunity. The adjuvant is a nanosized particle that combines two components: a short piece of synthetic DNA known as CpG oligodeoxynucleotide, which activates the immune sensor toll-like receptor 9 (TLR9), and a β-glucan called schizophyllan. Adjuvants are conventionally used to enhance the response to vaccines, but the researchers asked whether K3-SPG could act as a protective agent in its own right. The study was co-authored by PhD candidate Asuka Joy Tobuse of The University of Tokyo and Associate Project Scientist Kouji Kobiyama of the University of California San Diego, formerly a member of Ishii’s laboratory.

The first test was whether a single dose of K3-SPG delivered through the nose could protect mice against influenza A virus. The results were striking: treated mice lost less weight and had higher survival rates than untreated control mice. Remarkably, protection was still detectable 100 days after treatment, although it waned gradually over time. The team then extended the findings to a second pathogen, showing that the treatment also protected mice against SARS-CoV-2 in a susceptible mouse model. Together, these experiments suggested that a single nasal administration of the adjuvant could confer broad, temporary defense against unrelated respiratory viruses.

The route of administration proved to be a critical variable. Nasal treatment produced stronger protection than the same adjuvant given under the skin or into the bloodstream, an observation consistent with the idea that engaging immune cells locally in the respiratory tract is key to defending against airborne pathogens. Yet the nature of that protection was unexpected in one important respect. Despite improving survival and reducing lung damage, K3-SPG did not substantially reduce the amount of virus present in the lungs. The findings suggest that the treatment worked mainly by helping the host tolerate the infection—limiting tissue damage and preserving function—rather than by directly preventing viral replication.

To understand how this protection developed, the researchers used several analytical approaches, including single-cell RNA sequencing, which allows researchers to profile gene activity in individual cells. They found evidence of a two-stage response within the innate immune system. Macrophages, the scavenging and sentinel cells of the immune system, were important during the early phase of protection. Innate lymphoid cells, a group of tissue-resident immune cells that lack the antigen-specific receptors of conventional lymphocytes, became important later. Some of these innate lymphoid cells showed changes down to the chromatin level—the DNA–protein structure that helps regulate gene activity—suggesting that the adjuvant induced longer-lasting functional changes in these cells, potentially explaining how protection persisted for months.

The team also identified molecular requirements for the protective effect. The response depended on TLR9, the immune receptor activated by the CpG component of K3-SPG, as well as on TNF-α, an inflammatory signaling molecule involved in coordinating immune responses. These findings map a mechanistic pathway from the initial sensing of the adjuvant through inflammatory signaling to the recruitment and reprogramming of the cell types that sustain protection.

The concept of disease tolerance, which the K3-SPG findings bring into focus, represents a distinct strategy from the more familiar goal of pathogen clearance. In infectious disease research, scientists often separate resistance mechanisms, which directly reduce the burden of a pathogen in the body, from tolerance mechanisms, which limit the damage inflicted by both the pathogen and the immune response itself. The observation that treated mice carried similar amounts of virus in their lungs yet suffered less lung damage and survived at higher rates points toward tolerance as the dominant mode of protection in this case. This distinction matters practically as well as conceptually, because excessive inflammation in the lungs is a major contributor to severe outcomes in influenza and COVID-19, and interventions that dampen tissue injury without necessarily blocking replication could complement antiviral drugs that act on the virus directly.

The two-phase cellular architecture uncovered in the study also offers a plausible explanation for how innate protection can persist far longer than the lifespan of many individual immune cells. Macrophages are known to respond rapidly to danger signals and to communicate with surrounding tissue through cytokines and other mediators, making them well suited to an early-warning role. Innate lymphoid cells, meanwhile, are long-lived residents of mucosal tissues such as the lung, where they help maintain barrier integrity and coordinate responses to injury and infection. The chromatin-level changes observed in some of these cells resemble the epigenetic reprogramming that underlies trained immunity more broadly, in which prior stimulation leaves genes poised for faster or stronger activation upon later challenge. Such reprogramming can persist even as cells are renewed, providing a mechanistic bridge between a single treatment and protection measured months afterward.

The dependence of the protective effect on TLR9 is consistent with decades of work on how the innate immune system detects microbial DNA. TLR9 evolved to recognize unmethylated CpG motifs, which are characteristic of bacterial and viral genomes but relatively rare in mammalian DNA, making it a useful sensor of infection. Synthetic CpG oligodeoxynucleotides have been studied extensively as vaccine components precisely because they mimic this danger signal and can drive strong innate activation. Pairing CpG with schizophyllan, a β-glucan, adds a second layer of biological activity, since β-glucans are themselves associated with the induction of trained immunity in prior research. The nanosized particulate format of K3-SPG may further influence how the two components are delivered to immune cells in the respiratory tract, although the study’s mechanistic findings center on the TLR9 and TNF-α pathway.

The route-of-administration result carries implications for how such an approach might eventually be developed. Delivering immune stimulation directly to the nasal passages targets the mucosal surfaces where respiratory viruses first encounter the body, engaging the local population of macrophages and innate lymphoid cells that the study identified as central to protection. The inferior performance of subcutaneous and intravenous delivery in the mouse experiments suggests that systemic activation alone may not reproduce the localized, tissue-level changes needed for respiratory defense, and it underscores the importance of studying mucosal immunology on its own terms rather than extrapolating from injections.

Translating these findings into human use would require navigating several well-known challenges. Mouse models of influenza and SARS-CoV-2 infection, even susceptible engineered models, do not fully recapitulate human respiratory disease, and the durability of protection in mice may not predict the human response. TLR9 biology also differs between species in ways that have complicated the development of CpG-based therapeutics before. Safety is a further consideration, since deliberately activating inflammatory pathways such as TNF-α in the airways could carry risks, particularly for people with pre-existing respiratory conditions or autoimmune disease. The disclosure that two of the authors hold patents related to K3-SPG is standard for academic research with commercial potential, but it highlights that the adjuvant has an existing development history that could accelerate or complicate clinical translation.

Within the broader landscape of pandemic preparedness, the study contributes to a growing interest in pathogen-agnostic defenses. Strategies in this category, which also include research into broad-spectrum antivirals and pan-coronavirus vaccines, aim to provide value before the identity of a threat is known. An adjuvant-based prophylactic would occupy a distinctive niche: it would not require manufacturing a new product for each emerging virus, and it could in principle be stockpiled or deployed rapidly to bridge the interval until pathogen-specific vaccines become available. The 100 Days Mission, which aspires to have new vaccines ready within roughly three months of identifying a pandemic threat, leaves an unavoidable window of vulnerability that such innate protection could help cover. The mouse data showing detectable protection at 100 days after a single nasal dose align intriguingly with that timeline, though the authors themselves emphasize that demonstrating safety, effectiveness, and suitability in humans remains the essential next step before any such role could be realized.

Subject of Research: TLR9-activated vaccine adjuvant K3-SPG inducing trained innate immunity against respiratory viral infection in mice

Article Title: Could a vaccine adjuvant help prepare for future pandemics?

Article References: Could a vaccine adjuvant help prepare for future pandemics?. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: K3-SPG, vaccine adjuvant, trained immunity, innate immunity, TLR9, respiratory viruses, influenza A, SARS-CoV-2, macrophages, innate lymphoid cells, pandemic preparedness, TNF-α